Lung Cancer

The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.

The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.

HalioDx will perform immune biomarker exploratory work for the collaboration, which will focus on defining the profile of responder patients to Tedopi.

The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.

The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.

The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.

The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.

The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.

The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.